Volume 13, Number 8—August 2007
Multidrug-Resistant Bacteria in Southeastern Austria
Highlight and copy the desired format.
|EID||Badura A, Feierl G, Kessler HH, Grisold A, Masoud L, Wagner-Eibel U, et al. Multidrug-Resistant Bacteria in Southeastern Austria. Emerg Infect Dis. 2007;13(8):1256. https://dx.doi.org/10.3201/eid1308.070283|
|AMA||Badura A, Feierl G, Kessler HH, et al. Multidrug-Resistant Bacteria in Southeastern Austria. Emerging Infectious Diseases. 2007;13(8):1256. doi:10.3201/eid1308.070283.|
|APA||Badura, A., Feierl, G., Kessler, H. H., Grisold, A., Masoud, L., Wagner-Eibel, U....Marth, E. (2007). Multidrug-Resistant Bacteria in Southeastern Austria. Emerging Infectious Diseases, 13(8), 1256. https://dx.doi.org/10.3201/eid1308.070283.|
To the Editor: In many parts of the world, the proportions of methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci, and extended-spectrum β-lactamase (ESBL)–producing organisms in the family Enterobacteriaceae have increased remarkably during recent years (1). However, proportions of antimicrobial drug resistance vary substantially at national and regional levels. We describe antimicrobial drug resistance data for hospitalized patients and outpatients in southeast Austria.
A total of 690,967 clinical samples were collected from hospitalized patients and outpatients and analyzed at the microbiology laboratory of the Medical University of Graz during 1997–2006. Selected for resistance surveillance were nonduplicate isolates of S. aureus, Enterococcus faecium, E. faecalis, Escherichia coli, and Klebsiella spp. Antibiotic susceptibilities were determined by using disk diffusion and the VITEK2 system (bioMérieux, Marcy l’Etoile, France) with specific susceptibility test cards. Etest (AB Biodisk, Solna, Sweden) was used to confirm results. Test results were interpreted according to the recommendations of the Clinical and Laboratory Standards Institute (2).
The percentage of patients with vancomycin-resistant E. faecium and E. faecalis was low (median 0.4%) (Figure, panel A). In total, 10 E. faecium and 4 E. faecalis isolates with resistance to vancomycin were reported; most were from hospitalized patients. As in most European countries, human infections due to glycopeptide-resistant enterococci remain rare in Austria, although a high proportion of glycopeptide-resistant E. faecium was reported recently from animals used in food production (5).
Among E. coli isolates, no ESBL producers were noted in 1997. From 1998 through 2002, proportions of ESBL-producing E. coli were 0.06%–0.13%, which corresponds to 3–6 isolates per year. A subsequent increase of ESBL-producing E. coli isolates was noted, from 19 (0.3%) in 2003 to 148 (2.4%) in 2006 (Figure, panel B). Most (67%) ESBL-producing isolates found during 2003–2006 originated from community-acquired urinary tract infections. Resistance of E. coli to carbapenems was not reported during the study period. Among Klebsiella spp. isolates, 2 (0.2%) ESBL producers were observed during 1997. From 1998 through 2004, the prevalence of ESBLs among Klebsiella spp. ranged between 0.6% and 1.6%. In 2005 and 2006, the rate of ESBL-producing Klebsiella spp. increased to 3.8% (44 isolates) and 4.5% (55 isolates), respectively, and originated mainly from intensive care units (Figure, panel B). In 2005, a single Klebsiella pneumoniae isolate showed reduced susceptibility to imipenem (MIC 2 μg/mL) and to meropenem (MIC 4 μg/mL) and resistance to ertapenem (MIC >16 μg/mL). Nevertheless, production of ESBL by Enterobacteriaceae organisms is still rare in southeast Austria compared with other European countries (6). However, a dramatic increase of ESBL-producing E. coli and Klebsiella spp. has been observed during recent years.
The increase of ESBL-producing E. coli isolates in outpatients with urinary tract infections leads to serious treatment problems. Results from a recent study indicate that the increase of ESBL-producers in southeast Austria is caused mainly by the emergence of CTX-M–type ESBLs, which are increasingly being isolated from outpatients (7). The K. pneumoniae isolate found in 2005 represents the first ESBL-producing isolate not susceptible to carbapenems reported from Austria. Development of resistance to carbapenems in Enterobacteriaceae organisms has been reported increasingly, which substantially limits treatment options for persons with multidrug-resistant gram-negative infections (8).
Our data show insignificant changes in prevalence of MRSA and vancomycin-resistant enterococci in southeast Austria during the past decade but an alarming increase of multidrug-resistant ESBL-producing E. coli and Klebsiella spp. isolates in recent years. Detection of an ESBL-producing K. pneumoniae isolate with reduced susceptibility to carbapenems shows that pathogens with new mechanisms of resistance are emerging in this region.
- World Health Organization. Overcoming antimicrobial resistance: world health report on infectious diseases 2000. [cited 2006 June 16]. Available from http://www.who.int/infectious-disease-report/2000/other_versions/index-rpt2000_text.html
- Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Sixteenth informational supplement M100-S16. Wayne (PA): the Institute; 2006.
- Tiemersma EW, Bronzwaer SL, Lyytikainen O, Degener JE, Schrijnemakers P, Bruinsma N, Methicillin-resistant Staphylococcus aureus in Europe, 1999–2002. Emerg Infect Dis. 2004;10:1627–34.
- Witte W, Braulke C, Cuny C, Strommenger B, Werner G, Heuck D, Emergence of methicillin-resistant Staphylococcus aureus with Panton-Valentine leukocidin genes in central Europe. Eur J Clin Microbiol Infect Dis. 2005;24:1–5.
- Eisner A, Feierl G, Gorkiewicz G, Dieber F, Kessler HH, Marth E, High prevalence of VanA-type vancomycin-resistant enterococci in Austrian poultry. Appl Environ Microbiol. 2005;71:6407–9.
- Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev. 2005;18:657–86.
- Eisner A, Fagan EJ, Feierl G, Kessler HH, Marth E, Livermore DM, Emergence of Enterobacteriaceae isolates producing CTX-M extended-spectrum beta-lactamase in Austria. Antimicrob Agents Chemother. 2006;50:785–7.
- Nordmann P, Poirel L. Emerging carbapenemases in gram-negative aerobes. Clin Microbiol Infect. 2002;8:321–31.
- Figure. A) Proportion of methicillin resistance in Staphylococcus aureus and vancomycin resistance in Enterococcus faecium and E. faecalis in southeastern Austria, 1997–2006. B) Proportion of extended-spectrum β-lactamase–producing (ESBL) Escherichia coli and Klebsiella......
Please use the form below to submit correspondence to the authors or contact them at the following address:
Alexandra Badura, Institute of Hygiene, Medical University of Graz, Universitaetsplatz 4, 8010 Graz, Austria;
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: June 30, 2010
- Page last updated: June 30, 2010
- Page last reviewed: June 30, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)